|
1
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
2
|
Sequist LV, Martins RG, Spigel D, et al:
First-line gefitinib in patients with advanced non-small-cell lung
cancer harboring somatic EGFR mutations. J Clin Oncol.
26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yamamoto H, Toyooka S and Mitsudomi T:
Impact of EGFR mutation analysis in non-small cell lung
cancer. Lung Cancer. 63:315–321. 2009.
|
|
5
|
Kosaka T, Yatabe Y, Endoh H, Kuwano H,
Takahashi T and Mitsudomi T: Mutations of the epidermal growth
factor receptor gene in lung cancer: biological and clinical
implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar
|
|
6
|
Araki T, Yashima H, Shimizu K, et al:
Review of the treatment of non-small cell lung cancer with
gefitinib. Clin Med Insights Oncol. 6:407–421. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kobayashi S, Boggon TJ, Dayaram T, et al:
EGFR mutation and resistance of non-small-cell lung cancer
to gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar
|
|
8
|
Sequist LV, Waltman BA, Dias-Santagata D,
et al: Genotypic and histological evolution of lung cancers
acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oxnard GR, Arcila ME, Sima CS, et al:
Acquired resistance to EGFR tyrosine kinase inhibitors in
EGFR-mutant lung cancer: distinct natural history of patients with
tumors harboring the T790M mutation. Clin Cancer Res. 17:1616–1622.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eck MJ and Yun CH: Structural and
mechanistic underpinnings of the differential drug sensitivity of
EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta.
1804:559–566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maheswaran S, Sequist LV, Nagrath S, et
al: Detection of mutations in EGFR in circulating
lung-cancer cells. N Engl J Med. 359:366–377. 2008.
|
|
12
|
Inukai M, Toyooka S, Ito S, et al:
Presence of epidermal growth factor receptor gene T790M mutation as
a minor clone in non-small cell lung cancer. Cancer Res.
66:7854–7858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oh JE, An CH, Yoo NJ and Lee SH: Detection
of low-level EGFR T790M mutation in lung cancer tissues.
APMIS. 119:403–411. 2011.PubMed/NCBI
|
|
14
|
Fujita Y, Suda K, Kimura H, et al: Highly
sensitive detection of EGFR T790M mutation using colony
hybridization predicts favorable prognosis of patients with lung
cancer harboring activating EGFR mutation. J Thorac Oncol.
7:1640–1644. 2012. View Article : Google Scholar
|
|
15
|
Rosell R, Molina MA, Costa C, et al:
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in
erlotinib-treated advanced non-small-cell lung cancer patients with
EGFR mutations. Clin Cancer Res. 17:1160–1168. 2011. View Article : Google Scholar
|
|
16
|
Su KY, Chen HY, Li KC, et al: Pretreatment
epidermal growth factor receptor (EGFR) T790M mutation
predicts shorter EGFR tyrosine kinase inhibitor response duration
in patients with non-small-cell lung cancer. J Clin Oncol.
30:433–440. 2012.PubMed/NCBI
|
|
17
|
Toyooka S, Kiura K and Mitsudomi T:
EGFR mutation and response of lung cancer to gefitinib. N
Engl J Med. 352:21362005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sakuma Y, Yamazaki Y, Nakamura Y, et al:
WZ4002, a third-generation EGFR inhibitor, can overcome
anoikis resistance in EGFR-mutant lung adenocarcinomas more
efficiently than Src inhibitors. Lab Invest. 92:371–383.
2012.PubMed/NCBI
|
|
19
|
Regales L, Gong Y, Shen R, et al: Dual
targeting of EGFR can overcome a major drug resistance mutation in
mouse models of EGFR mutant lung cancer. J Clin Invest.
119:3000–3010. 2009.PubMed/NCBI
|
|
20
|
Asano H, Toyooka S, Tokumo M, et al:
Detection of EGFR gene mutation in lung cancer by
mutant-enriched polymerase chain reaction assay. Clin Cancer Res.
12:43–48. 2006.PubMed/NCBI
|
|
21
|
Li J, Wang L, Mamon H, Kulke MH, Berbeco R
and Makrigiorgos GM: Replacing PCR with COLD-PCR enriches variant
DNA sequences and redefines the sensitivity of genetic testing. Nat
Med. 14:579–584. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Luthra R and Zuo Z: COLD-PCR finds hot
application in mutation analysis. Clin Chem. 55:2077–2078. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Milbury CA, Li J and Makrigiorgos GM:
COLD-PCR-enhanced high-resolution melting enables rapid and
selective identification of low-level unknown mutations. Clin Chem.
55:2130–2143. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Song C, Milbury CA, Li J, Liu P, Zhao M
and Makrigiorgos GM: Rapid and sensitive detection of KRAS mutation
after fast-COLD-PCR enrichment and high-resolution melting
analysis. Diagn Mol Pathol. 20:81–89. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fan H and Gulley ML: DNA extraction from
fresh or frozen tissues. Methods Mol Med. 49:5–10. 2001.PubMed/NCBI
|
|
26
|
Goto K, Satouchi M, Ishii G, et al: An
evaluation study of EGFR mutation tests utilized for
non-small-cell lung cancer in the diagnostic setting. Ann Oncol.
23:2914–2919. 2012.
|
|
27
|
Tokumo M, Toyooka S, Kiura K, et al: The
relationship between epidermal growth factor receptor mutations and
clinicopathologic features in non-small cell lung cancers. Clin
Cancer Res. 11:1167–1173. 2005.PubMed/NCBI
|
|
28
|
Do H, Krypuy M, Mitchell PL, Fox SB and
Dobrovic A: High resolution melting analysis for rapid and
sensitive EGFR and KRAS mutation detection in
formalin fixed paraffin embedded biopsies. BMC Cancer. 8:1422008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ueno T, Toyooka S, Suda K, et al: Impact
of age on epidermal growth factor receptor mutation in lung cancer.
Lung Cancer. 78:207–211. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Matsuo K, Ito H, Yatabe Y, et al: Risk
factors differ for non-small-cell lung cancers with and without
EGFR mutation: assessment of smoking and sex by a
case-control study in Japanese. Cancer Sci. 98:96–101. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bell DW, Gore I, Okimoto RA, et al:
Inherited susceptibility to lung cancer may be associated with the
T790M drug resistance mutation in EGFR. Nat Genet. 37:1315–1316.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Soh J, Okumura N, Lockwood WW, et al:
Oncogene mutations, copy number gains and mutant allele specific
imbalance (MASI) frequently occur together in tumor cells. PLoS
One. 4:e74642009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pao W, Miller VA, Politi KA, et al:
Acquired resistance of lung adenocarcinomas to gefitinib or
erlotinib is associated with a second mutation in the EGFR kinase
domain. PLoS Med. 2:e732005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ohtsuka K, Ohnishi H, Kurai D, et al:
Familial lung adenocarcinoma caused by the EGFR V843I
germ-line mutation. J Clin Oncol. 29:e191–e192. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
van Noesel J, van der Ven WH, van Os TA,
et al: Activating germline R776H mutation in the epidermal growth
factor receptor associated with lung cancer with squamous
differentiation. J Clin Oncol. 31:e161–e164. 2013.PubMed/NCBI
|
|
36
|
Chmielecki J, Foo J, Oxnard GR, et al:
Optimization of dosing for EGFR-mutant non-small cell lung cancer
with evolutionary cancer modeling. Sci Transl Med. 3:90ra592011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Govindan R, Ding L, Griffith M, et al:
Genomic landscape of non-small cell lung cancer in smokers and
never-smokers. Cell. 150:1121–1134. 2012. View Article : Google Scholar : PubMed/NCBI
|
